PARIS, June 14 (Reuters) - France's DrugAbuse Science (DAS), which develops treatments tackling drug and alcohol addiction, aims to raise 20 million euros ($25.2 million) in an initial public offering of shares. It said on Wednesday it would issue about 1.8 million shares at 11.10 euros each and sell them via a private placement to specialised investors as it seeks to fund late-stage clinical trials of drug Naltrexone Depot, which treats alcohol dependence.
